Photoactive Platinum(II) Azopyridine Complexes

Area of Science:

• Inorganic Chemistry
• Photochemistry
• Materials Science

Background:

• Platinum(II) complexes are investigated for their photophysical and biological properties.
• The phenylazopyridine (Ph-azpy) ligand offers tunable electronic properties through phenyl ring substitution.
• Monodentate ligands (Cl, N3) and substituents on the Ph-azpy ligand influence complex behavior.

Purpose of the Study:

• Synthesize and characterize novel platinum(II) complexes with Ph-azpy ligands.
• Investigate the impact of ligand substitution and monodentate ligands on spectral and photoactivation properties.
• Evaluate the potential of these complexes in biological applications, particularly photodynamic therapy.

Main Methods:

• Synthesis and characterization of platinum(II) complexes [Pt(p-R-Ph-azpy)X2].
• Time-dependent density functional theory (TD-DFT) calculations for electronic structure analysis.
• UV-visible absorption spectroscopy to study electronic transitions.
• Photolysis studies in solution under UVA and visible light irradiation.
• Preliminary biological screening, including cellular uptake and cytotoxicity assays.

Main Results:

• Complexes exhibit low-lying unoccupied orbitals with σ-antibonding character.
• Absorption bands are assigned to ligand-centered or metal-to-ligand charge-transfer transitions.
• Substituents (NMe2, OH/O-) on the Ph-azpy ligand cause a redshift in absorption spectra.
• Diazido complexes show photoactivity, with varying light sensitivity based on substituents.
• The phenolato complex demonstrates rapid nuclear uptake in HaCaT keratinocytes and increased cytotoxicity upon UVA irradiation.

Conclusions:

• Electronic properties and photoactivity of platinum(II)-Ph-azpy complexes are tunable via ligand design.
• Diazido complexes are promising photoactive agents, especially the phenolato derivative.
• The phenolato complex exhibits efficient nuclear targeting and photo-enhanced cytotoxicity, suggesting potential in photodynamic cancer therapy.